Please excuse the green bed sheet in the background. We were trying different techniques for effects and obviously it did not work! Charts and Commentary on $ATHX and others.. please note; the charts on the right side get cut off…
Tag: stock
Athersys, Inc. (ATHX) Beginning Due Diligence (chart technicals to come in seperate post)
Beginning points of Due Diligence for Athersys (ATHX) I am long the stock from $1.24. My Short Term catalyst Price Target opinion is $1.55 to $1.75, and $2.75 based on if positive Phase II data is reported. Multiple 2013 Catalysts…
Midweek Biopharma Update – $BLRX $PATH $NEPT and others + Twitter bashers (Video)
Midweek Biopharma Update – $BLRX $PATH $NEPT and others + Twitter bashers commentary. YouTube Video, enjoy!
BioTech wrap up for December 21st $ALXA $FOLD
$ALXA and $FOLD Commentary, Merry Christmas and a happy new year to everyone!
ArQule: A Strong Speculation BioPharma Poised For A Quick Move Up On Near Term Catalyst
ArQule (NASDAQ: ARQL) ArQule engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate Tivantinib (ARQ 197) is an inhibitor of the c-Met receptor tyrosine kinase, which is in Phase…
Osiris Therapeutics (OSIR) Catalyst Trade Thesis
Osiris Therapeutics (OSIR) Osiris expects to have data in hand (final data collection date for primary outcome measure) by the end of this year for the Phase III evaluation of Prochymal (remestemcel-L), which is an adult human stem cells treatment…
Small Cap Biotechs That Could Make Big Moves This Week
Star Scientific (STSI) Star Scientific engages in the manufacture, distribution, and sale of consumer products, dietary supplements, and dissolvable tobacco. They also have several products which have a botanical-based component designed to treat a range of neurological conditions including Alzheimer’s…
My video commentary on The Negative Article about Alexza 12/5/12, written by Jason Napodano
My video commentary on The Negative Article about Alexza 12/5/12, written by Jason Napodano, CFA which can be found at http://propthink.com/alexza-meaningfully-overvalued-following-its-latest-rally/4120
3 Small Cap Bio-Pharmas With Trade Catalysts And Speculation Investment Potential
Zogenix (ZGNX) engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the…
11/30/12 Catalyst Trade And Speculation Investment List
Alexza Pharma (NASDAQ: ALXA) Alexza engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes…
